Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

This groundbreaking development may enable treatments for inflammatory diseases such as Crohn's and colitis.Researchers at ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.

Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®? (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Request To Download Free Sample of This Strategic Report@ Highlighted with 59 tables and 54 figures, this 141-page report ?Asia Pacific Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 62 tables and 55 figures, this 142-page report ?Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

A revolutionary personalized cancer vaccine developed by Russia’s Gamaleya Research Institute of Epidemiology and ...